Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.

Blood·2026
Same author

Retraction notice to "Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways" [Biomedicine & Pharmacotherapy 161 (2023) 114512].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma.

Drug delivery·2026
Same author

Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones.

Cell reports·2026
Same author

A roadmap for systematic humanization of a chimeric antigen receptor: preclinical validation of a humanized CD22 scFv as a model.

Experimental hematology·2026
Same author

Hippo signalling pathway mediates oncogenic properties of NAB2::STAT6 in solitary fibrous tumour.

Cellular oncology (Dordrecht, Netherlands)·2026

Related Experiment Video

Updated: May 29, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Rene Rodriguez1, Ruth Rubio, Pablo Menendez

  • 1Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research (GENyO), Parque Tecnológico de Ciencias de la Salud, Granada, Spain. rene.rodriguez@genyo.es

Cell Research
|September 21, 2011
PubMed
Summary

Mesenchymal stem cells (MSCs) show promise in clinical applications but can also be linked to cancer. Research is exploring MSC-based models to understand sarcoma development and create targeted therapies.

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Area of Science:

  • Stem Cell Biology
  • Oncology
  • Regenerative Medicine

Background:

  • Multipotent mesenchymal stem cells (MSCs) are widely used in clinical settings.
  • While generally safe, MSCs have a complex relationship with cancer, potentially promoting or inhibiting tumor growth.
  • Evidence suggests MSCs may be the cell of origin for certain sarcomas.

Purpose of the Study:

  • To review existing MSC-based models of sarcoma.
  • To discuss mechanisms of MSC transformation and sarcomagenesis.
  • To highlight the need for further research into human MSC-based sarcoma models.

Main Methods:

  • Comprehensive literature review of MSC-based sarcoma models.
  • Analysis of experimental data linking MSCs to cancer.
  • Discussion of genetic interventions and transgenic mouse models.

Main Results:

  • MSCs are implicated in sarcomagenesis, with evidence from animal models.
  • The precise mechanisms of MSC transformation into sarcoma cells are not fully understood.
  • Existing models provide insights but require further development, especially using human MSCs.

Conclusions:

  • MSC-based models are crucial for understanding sarcoma etiology and pathogenesis.
  • Further research is needed to elucidate MSC transformation mechanisms.
  • Developing human MSC-based sarcoma models will aid in targeted therapy development.